Do Caregivers Feel Supported in Administering Cannabis in Dementia Care? 

Administering medication in dementia care can be challenging, especially when treatments involve unlicensed or unfamiliar products such as cannabis-based medicinal products (CBPMs). While some caregivers report improved calmness and easier symptom management, others say they lack guidance on safe dosing, side effect recognition, and record-keeping. 

According to NHS England and NICE guideline NG144, CBPMs are only licensed for specific conditions such as epilepsy and multiple sclerosis, not dementia. When used off-label in older adults, prescribers must ensure that families understand dosing instructions, storage, and how to report sedation, falls, or confusion. 

The MHRA’s 2020 guidance requires that any caregiver administering CBPMs receives written instructions directly from a specialist prescriber and logs use under a formal governance framework. Similarly, the GMC emphasises that clinicians retain full responsibility for oversight, even if caregivers handle the medication day to day. 

What Research Shows About Caregiver Experience 

Evidence from recent studies suggests that proper caregiver training can improve safety and confidence. A 2024 Frontiers in Aging Neuroscience study found that CBD-rich oil reduced neuropsychiatric symptoms in Alzheimer’s disease and significantly lowered caregiver distress. Caregivers reported better emotional wellbeing and less frustration managing agitation and restlessness. 

Similarly, the 2023 Australian double-blind trial and Swiss MedCanDem study found that structured caregiver involvement in dosing and monitoring improved treatment adherence and reduced dosing errors. International programmes in Israel and Canada have also shown that remote supervision and caregiver education can make CBPM administration safer and more effective. 

However, NICE and MHRA continue to warn that without clinical supervision, cannabis use may increase sedation or confusion in older adults. The BMJ’s 2023 review stresses that caregiver support systems are essential to prevent unsafe or inconsistent dosing in dementia care. 

Clinical Bottom Line 

• CBPMs are not licensed for dementia and must be prescribed only by specialists. 

• Caregivers need clear written dosing guidance and access to clinical support. 

• Structured caregiver education reduces stress and dosing errors. 

• NICE and MHRA require shared decision-making and monitoring frameworks. 

• Improved caregiver training enhances safety, consistency, and wellbeing. 

Role Of AlleviMed 

Educational organisations such as AlleviMed offer information about the UK’s legal and clinical framework for medical cannabis. They explain how caregiver involvement should work under supervision and provide accessible resources for families navigating compassionate-use settings. AlleviMed does not prescribe or recommend treatment but supports informed, safe participation in care. 

Takeaway 

Caregivers often feel more confident and less burdened when supported by clear medical guidance and structured follow-up. While evidence suggests improved wellbeing when cannabis is used responsibly, these benefits depend on training, supervision, and strict adherence to national safety standards. Professional oversight remains the cornerstone of safe dementia care involving CBPMs.